Immunome (IMNM) Financials: Revenue & Earnings

IMNM price $18.67 -0.10 -0.53%

Ticker
IMNM
Price
$18.67
Change
-0.10 -0.53%
Market cap ?
$2.20B
P/E ?
-7.04
Forward P/E ?
25.57
Dividend yield ?
0.00%
Beta ?
2.13
Sector
Healthcare
Industry
Biotechnology

Financials

20182019202020212022202320242025
000001401800090410006941000

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan…

Fair value

IMNM fair value $17.14. Price $18.67. Price is 9% above fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 739.71K. Growth 20.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 12.00% (beta 2.0). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 118.00M. Net debt -649.63M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Compare IMNM

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-05—-0.61—153.85K
2026-08-11-0.65-0.51—166.67K
2026-05-12-0.48-0.60—222.22K
2026-03-03-0.75-0.59—876.03K
2025-11-06-0.65-0.57—850.00K
2025-08-06-0.50-0.524.01M833.33K
2025-05-12-0.52-0.662.93M457.14K
2025-03-19-0.84-0.682.74M3.15M
2024-11-13-0.78-0.602.91M3.16M
2024-08-12-0.49-0.382.36M2.55M
2024-05-14-2.51-0.691.03M2.80M
2024-03-28-4.21-0.283.84M2.07M
2023-11-09-0.36-0.173.56M3.56M
2023-08-09-0.46-0.164.26M—
2023-05-05-0.350.592.36M—
2023-03-16-0.640.67——
2022-11-14-0.75-0.76——
2022-08-05-0.74-0.75——
2022-05-12-0.96-0.69——
2022-03-28-0.66-0.81——
2021-11-15-0.65-0.50——
2021-08-16-0.46-0.39—4.70M
2021-05-12-0.37-0.41——
2021-03-25-0.40-0.29——
2020-11-16-7.52-0.38——
2020-10-05-0.29———
2020-03-31-0.47———
2019-12-31-0.51———
2019-09-30-0.48———
2019-06-30-2.19———
2019-03-31-2.19———

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-09-11Higgins JackBuy18.00K$1.3524.30K
2026-09-11Higgins JackBuy18.00K$1.3524.30K
2026-09-11Higgins JackSell13.20K$25.32334.22K
2026-09-11Higgins JackSell8.80K——
2026-08-12Barchas IsaacSell11.05K$27.25301.06K
2026-08-11Barchas IsaacSell62.29K$26.231.63M
2026-08-10Barchas IsaacSell10.12K$26.07263.96K
2026-08-07Barchas IsaacSell15.25K$26.06397.36K
2026-08-06Barchas IsaacSell20.84K$26.06543.09K
2026-08-04Horn KinneySell40.25K$10.60426.65K
2026-08-04Horn KinneyBuy40.25K$10.60426.65K
2026-08-04Horn KinneySell50.37K$12.92650.73K
2026-08-04Horn KinneyBuy50.37K$12.92650.73K
2026-08-04Horn KinneySell90.62K$25.092.27M
2026-07-23Horn KinneyBuy62.50K$22.011.38M
2026-07-23Horn KinneyBuy31.25K——
2026-07-23Tsai PhilipBuy38.25K——
2026-07-23Tsai PhilipBuy76.50K$22.011.68M
2026-07-23Stoneman Sandra G.Buy76.50K$22.011.68M
2026-07-23Stoneman Sandra G.Buy38.25K——
2026-07-23Higgins JackBuy76.50K$22.011.68M
2026-07-23Higgins JackBuy38.25K——
2026-07-23Rosett MaxBuy47.25K——
2026-07-23Rosett MaxBuy94.50K$22.012.08M
2026-07-23Lechleider RobertBuy108.00K$22.012.38M
2026-07-23Lechleider RobertBuy54.00K——
2026-07-23SIEGALL CLAY BBuy180.00K——
2026-07-23SIEGALL CLAY BBuy360.00K$22.017.92M
2026-07-07Horn KinneySell1.09K$12.9214.11K
2026-07-07Horn KinneyBuy1.09K$12.9214.11K
2026-07-07Horn KinneySell1.09K$25.0027.30K
2026-07-07Barchas IsaacSell16.91K$24.20409.13K
2026-07-06Barchas IsaacSell83.09K$24.112.00M
2026-07-02Lechleider RobertSell55.00K$8.73480.15K
2026-07-02Lechleider RobertBuy55.00K$8.73480.15K
2026-07-02Lechleider RobertSell22.71K$21.95498.57K
2026-07-02Lechleider RobertSell16.21K$22.76369.03K
2026-07-02Lechleider RobertSell16.07K$23.44376.73K
2026-07-02Barchas IsaacSell75.67K$22.351.69M
2026-07-02Barchas IsaacSell24.34K$23.33567.74K
2026-06-30Barchas IsaacSell101.05K$21.122.13M
2026-06-25Lechleider RobertSell55.00K$8.73480.15K
2026-06-25Lechleider RobertBuy55.00K$8.73480.15K
2026-06-25Lechleider RobertSell40.58K$19.56793.74K
2026-06-25Lechleider RobertSell14.42K$20.66297.92K
2026-06-15Rosett MaxBuy60.00K$1.0563.00K
2026-06-15Rosett MaxSell60.00K$18.231.09M
2026-06-15Rosett MaxSell60.00K$1.0563.00K
2026-06-10SWAIN SANDRA MBuy9.90K$18.16179.73K
2026-06-10WAGENHEIM PHILIPBuy9.90K$18.16179.73K
2026-06-10BIENAIME JEAN JACQUESBuy9.90K$18.16179.73K
2026-06-10Boylan James PBuy9.90K$18.16179.73K
2026-06-10Barchas IsaacBuy9.90K$18.16179.73K
2026-06-10SCHAFER CAROLBuy9.90K$18.16179.73K
2026-06-05BIENAIME JEAN JACQUESBuy1.00K$19.2719.27K
2026-06-05BIENAIME JEAN JACQUESSell500$19.449.72K
2026-06-05BIENAIME JEAN JACQUESBuy3.50K$19.4668.11K
2026-06-05BIENAIME JEAN JACQUESBuy6.00K$19.48116.88K
2026-06-05BIENAIME JEAN JACQUESSell10.00K$19.41194.10K
2026-05-15BIENAIME JEAN JACQUESBuy5.00K$20.70103.50K
2026-04-02Higgins JackSell9.44K$21.64204.24K
2026-04-02Rosett MaxBuy39.71K$1.3553.61K
2026-04-02Rosett MaxBuy31.85K$1.0533.44K
2026-04-02Rosett MaxSell31.85K$1.0533.44K
2026-04-02Rosett MaxSell63.66K$21.911.39M
2026-04-02Rosett MaxSell1.34K$22.4830.21K
2026-04-02Rosett MaxSell39.71K$1.3553.61K
2026-03-30Higgins JackSell6.29K——
2026-03-27SIEGALL CLAY BBuy25.45K$19.67500.60K
2026-03-23WAGENHEIM PHILIPSell28.20K$20.65582.33K
2026-03-20WAGENHEIM PHILIPSell36.80K$20.47753.30K
2026-03-11BIENAIME JEAN JACQUESBuy1.00K$21.5521.55K
2026-03-10BIENAIME JEAN JACQUESBuy1.00K$22.1222.12K
2025-12-30SIEGALL CLAY BBuy4.73K$21.15100.02K
2025-12-22Barchas IsaacSell371.95K$21.728.08M
2025-12-22Barchas IsaacSell11.25K$22.34251.35K
2025-12-19Higgins JackSell1.00K——
2025-12-19Higgins JackSell1.00K——
2025-12-19Higgins JackSell1.00K——
2025-12-19Higgins JackBuy1.00K——
2025-12-19SIEGALL CLAY BBuy7.28K$20.48149.05K
2025-12-19SIEGALL CLAY BSell200.00K——
2025-12-19Tsai PhilipBuy10.00K$20.49204.90K
2025-12-18SIEGALL CLAY BBuy46.51K$21.50999.99K
2025-09-10Higgins JackSell22.00K$1.3529.70K
2025-09-10Higgins JackBuy22.00K$1.3529.70K
2025-07-29Tsai PhilipBuy190.00K$10.602.01M
2025-07-29Rosett MaxBuy207.00K$10.602.19M
2025-07-29Lechleider RobertBuy242.00K$10.602.57M
2025-07-29Horn KinneyBuy161.00K$10.601.71M
2025-07-29Higgins JackBuy196.00K$10.602.08M
2025-07-29SIEGALL CLAY BBuy800.00K$10.608.48M
2025-07-29Stoneman Sandra G.Buy190.00K$10.602.01M
2025-06-10Boylan James PBuy18.86K$9.57180.53K
2025-06-10SCHAFER CAROLBuy18.86K$9.57180.53K
2025-06-10WAGENHEIM PHILIPBuy18.86K$9.57180.53K
2025-06-10Barchas IsaacBuy18.86K$9.57180.53K
2025-06-10BIENAIME JEAN JACQUESBuy18.86K$9.57180.53K
2025-06-10SWAIN SANDRA MBuy18.86K$9.57180.53K
2025-06-03BIENAIME JEAN JACQUESBuy5.00K$9.3846.90K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 211, holders +3 vs prior quarter. Ownership 104.99%.

HolderSharesChangeChange %Value
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.19.68M3.31M+20.24%416.95M
FMR LLC16.99M17.60K+0.10%359.97M
BLACKROCK, INC.8.81M636.82K+7.80%186.59M
STATE STREET CORP5.49M94.72K+1.75%116.43M
WELLINGTON MANAGEMENT GROUP LLP5.21M478.24K+10.11%110.40M
REDMILE GROUP, LLC4.91M-647.29K-11.64%104.08M
PRIMECAP MANAGEMENT CO/CA/4.58M-206.80K-4.32%97.08M
VANGUARD CAPITAL MANAGEMENT LLC4.55M121.59K+2.74%96.44M
DRIEHAUS CAPITAL MANAGEMENT LLC4.35M246.24K+6.01%92.09M
ENAVATE SCIENCES GP, LLC3.61M00.00%76.58M
GEODE CAPITAL MANAGEMENT, LLC2.75M194.22K+7.58%58.39M
MORGAN STANLEY2.41M-433.65K-15.26%51.02M
SILVERARC CAPITAL MANAGEMENT, LLC2.02M166.73K+9.01%42.74M
JPMORGAN CHASE & CO1.85M-929.29K-33.45%38.99M
PRICE T ROWE ASSOCIATES INC /MD/1.77M-1.09M-37.97%37.58M
SOFINNOVA INVESTMENTS, INC.1.72M18.41K+1.08%36.45M
READYSTATE ASSET MANAGEMENT LP1.61M303.96K+23.35%34.03M
GOLDMAN SACHS GROUP INC1.51M411.01K+37.31%32.05M
VANGUARD PORTFOLIO MANAGEMENT LLC1.35M342.00K+33.96%28.58M
PRINCIPAL FINANCIAL GROUP INC1.35M-29.51K-2.14%28.55M
BNP PARIBAS ASSET MANAGEMENT HOLDING S.A.1.25M152.44K+13.89%26.49M
WOODLINE PARTNERS LP1.00M-575.00K-36.50%21.20M
NORTHERN TRUST CORP968.35K69.20K+7.70%20.52M
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.886.19K886.19KNew18.78M
CHARLES SCHWAB INVESTMENT MANAGEMENT INC886.19K34.40K+4.04%18.78M

Earnings and financials

Immunome, Inc. (IMNM) trades at $18.67, with a market cap of $2.20B and a trailing P/E of -7.04. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

20182019202020212022202320242025
000001401800090410006941000

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Immunome (IMNM) Financials: Revenue & Earnings

IMNM$18.67-0.10 -0.53%

$2.20B

Market Cap

-7.04

P/E

25.57

Forward P/E

—

Score

Price History